about
Emerging preclinical pharmacological targets for Parkinson's diseaseImmunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein AggregationNeuromolecular imaging, a nanobiotechnology for Parkinson's disease: advancing pharmacotherapy for personalized medicine.α-Synuclein and nonhuman primate models of Parkinson's diseaseBent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease.Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's diseaseImmunoliposomes doubly targeted to transferrin receptor and to α-synuclein.Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.Parkinson's disease and prion disease: Straining the comparison.The role of nonhuman primate models in the development of cell-based therapies for Parkinson's disease.Historical perspective of cell transplantation in Parkinson's disease.Vertebrate food products as a potential source of prion-like α-synuclein.Cortical gray and subcortical white matter associations in Parkinson's disease.Critical appraisal of pathology transmission in the α-synuclein fibril model of Lewy body disorders.Nonhuman Primate Models of Neurodegenerative Disorders.Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects.miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson's disease.Oleuropein aglycone stabilizes the monomeric α-synuclein and favours the growth of non-toxic aggregates.
P2860
Q26764724-13897BC4-DD00-4F9D-AA8C-342671F2A10AQ26781130-5201810C-4C5C-4CD8-BC9A-97587A28B953Q30394681-5530F48E-3AC3-48E9-A333-9C5D8BC8B14BQ36157306-8EB4E420-EAE0-4AC4-8D15-BB7194EE57CAQ36373170-037F7DF9-D268-4E5A-A787-36D3F9B6803DQ37197984-F7AFE19E-9F56-4EC3-B370-969D2AE41191Q37474296-FE7E8C44-C26E-4370-86A1-DE8593D4DCB2Q38541943-DA75EEF5-BD66-4F87-ABF4-9E0B352F48F0Q38598375-CB1277B8-4039-489D-94BE-D08B13F84845Q38697396-3C4FD60D-E640-4003-8A8F-4AA777BC01AAQ39192172-458F3BB4-671F-4CF1-ADFB-A102D1E21CD6Q39429728-FB3305BB-51D7-46B2-90A3-418EC0EA4A95Q46252338-1D4919B6-0CA9-4828-92FE-583DE2E28A3DQ47144107-226760C4-336F-4389-9E9F-75DDC3F00C98Q47619917-D86D24F4-35FC-4A21-B61B-EC5E9F2003CCQ47687033-24D91EB8-842E-4C1B-8B82-72851925B9DCQ52589683-DC35C764-29DB-4AF0-991E-1A61E08B8AECQ52801531-F8EA96BD-305B-4FC3-B2CA-B61E7B782A91Q55341800-DADAEE66-64BB-4954-B6EC-BA4EC357FC29
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The prion hypothesis of Parkinson's disease.
@en
type
label
The prion hypothesis of Parkinson's disease.
@en
prefLabel
The prion hypothesis of Parkinson's disease.
@en
P2860
P1476
The prion hypothesis of Parkinson's disease.
@en
P2093
Yaping Chu
P2860
P2888
P356
10.1007/S11910-015-0549-X
P577
2015-05-01T00:00:00Z
P6179
1037647485